SaaS Development for UK MedTech -- Compliance Built In

UK MedTech SaaS Market 2026

UK MedTech SaaS in 2026 is shaped by three regulatory catalysts: (1) MHRA Software as a Medical Device (SaMD) regulatory guidance (MHRA expects software meeting medical device definition to be UKCA-marked), (2) NHS DTAC (Digital Technology Assessment Criteria -- all software procured by NHS must pass 5-domain assessment), (3) NICE ESF (Evidence Standards Framework -- NHS procurement increasingly requires Tier 3b clinical evidence for AI clinical decision support). UK MedTech SaaS business models: (a) NHS Trust licensed SaaS (per-trust annual licence -- GBP20,000-GBP100,000/trust), (b) NHS Framework Agreement (Crown Commercial Service G-Cloud 14 or NHS National Framework -- procurement simplified), (c) US market entry (UK UKCA certification -- CE marking mutual recognition lost post-Brexit -- requires separate FDA 510(k) for US).

MHRA SaMD Classification for MedTech SaaS

MHRA SaMD classification decision tree: (1) Does the software influence clinical decisions or treatment? If yes, it is SaMD. (2) Is it intended for a specific medical purpose (diagnosis, monitoring, prediction, treatment)? If yes, continue. (3) Risk class: Class I (low risk -- information, administrative), Class IIa (moderate risk -- aids clinical decision), Class IIb (higher risk -- performs clinical analysis), Class III (high risk -- life-supporting). UK post-Brexit classification: UK uses MHRA MDR 2002 (amended) -- similar to EU MDR 2017 but UKCA marking (not CE). Notified Body: MHRA-designated UK Notified Bodies (BSI Assurance UK, SGS, Intertek). MHRA registration: all MedTech SaaS must register on MHRA DESH (Device Establishment and Service Helpdesk).

NHS DTAC for MedTech SaaS

NHS DTAC all 5 domains are required for any MedTech SaaS procured by NHS. Domain 4 (Clinical Safety) for MedTech: DCB0129 (clinical safety standard for health software) requires: (1) clinical safety officer (CSO) appointment (qualified clinician), (2) hazard log (identify all hazards associated with software use), (3) safety case (argument that risks are reduced to as low as reasonably practicable -- ALARP), (4) clinical safety management plan. DCB0129 vs MHRA SaMD: software can be DTAC compliant (DCB0129) without being MHRA Class IIa/IIb (UKCA) -- DCB0129 applies to all health software, MHRA SaMD regulation applies only to software meeting medical device definition. ClickMasters practice: complete DCB0129 for all NHS software, determine MHRA SaMD classification separately.

NICE ESF Tier 3b Evidence for MedTech AI

NICE Evidence Standards Framework Tier 3b: AI clinical decision support using algorithmically-generated outputs. Evidence requirements: (1) clinical validation (prospective study -- randomised controlled trial or well-designed cohort), (2) economic evaluation (cost per QALY, cost per outcome), (3) real-world data plan (ongoing monitoring post-deployment), (4) equalities evidence (performance across demographic subgroups), (5) service readiness (implementation support -- training, change management). NICE ESF is not yet mandatory but NHS England procurement increasingly expects Tier 3b evidence for AI clinical tools. ClickMasters NICE ESF support: study design, statistical analysis plan, health economic model. Typical cost: GBP30,000-GBP80,000 for full NICE ESF Tier 3b evidence package.

MHRA SaMD

UKCA

IEC 62304

ISO 14971

DCB0129

NHS DTAC

NICE ESF

UK GDPR Article 9